secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001193125-26-034564
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Prelude's JAK2V617F inhibitor PRT12396; Phase 1 to start by Q2 2026
--------------------------------------------------------------------------------

- FDA cleared IND for PRT12396, a mutant-selective JAK2V617F inhibitor for myeloproliferative neoplasms.
- Phase 1 study in polycythemia vera and myelofibrosis to initiate by Q2 2026.
- PRT12396 is subject to an exclusive option agreement with Incyte (announced Nov 2025).
- JAK2V617F mutation drives ~95% of PV, 60% of ET, and 55% of MF cases.
- Open-label Phase 1 will assess safety, efficacy, and PK profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526034564/0001193125-26-034564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526034564/prld-20260129.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-034564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer